DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

for

Permanent Record

and the

Appointments and Promotions Committee

Last Updated: December 16, 2020

**Name:** John Alexander Bartlett, M.D.

**Primary academic appointment:** Department of Internal Medicine

**Present academic rank and title:** Professor of Medicine

**Date and rank of first Duke faculty appointment:** July 1, 1987 - Associate in Medicine

**Medical Licensure:** Licensed, National Board of Medical Examiners, 1982

Licensed, State of North Carolina, 1982

License Number 26488

Licensed, Medical Board of Tanganyika, 2004

**Specialty certification and dates:** Certified, American Board of Internal Medicine, Internal Medicine, 1984

Certified, American Board of Internal Medicine, Infectious Diseases, 1988

**Date of birth:** March 7, 1955

**Place:** Rochester, NY

**Citizen of:** United States

**Education:**   **Place Date Degree**

High School Pittsford High School 1973

College Harvard University 1977 AB cum laude

Graduate or University of Virginia 1981 MD

Professional School

**Professional training and academic career:**

1981-1982 Intern, Duke University Medical Center

1982-1984 Resident, Duke University Medical Center

1983 Assistant Chief Resident, Duke University Medical Center

1984 Chief Resident, Durham County General Hospital

1985-1987 Fellow, Division of Infectious Diseases, Duke University Medical Center

1987-1988 Associate in Medicine, Division of Infectious Diseases, Duke University Medical Center

1987-2004 Director, Duke University Medical Center Adult Infectious Diseases Clinic

1989-1996 Assistant Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center

1990-present Principal Investigator, Duke University Adult AIDS Clinical Trials Unit

1992-present Director of Clinical Research, Duke University Center for AIDS Research

1993-2003 Associate Director, Clinical Research Unit, Duke University Medical Center

1996-present Senior Fellow, Duke University Center for Health Policy Research and Education

1996-2001 Associate Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center

2001-present Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center

2003-present Fellow, Health Inequalities Program, Sanford Institute of Public Policy, Duke University

2004-present Professor of Nursing, Duke University Medical Center

2004-2008 Principal Investigator, International Studies of AIDS-associated Co-infections

2004-present Director of Research, AIDS International Training Research Program

2005-present Co-Director, Duke University Center for AIDS Research

2006-present Professor of Medicine, Kilimanjaro Christian Medical College

2008-2020 Associate Director for Research, Duke University Global Health Institute

2010-2012 Director of Post-doctoral Fellowship Training, Duke Global Health Institute

2010-2015 Director, HIV-associated Malignancies Research Training Program

2012-present Professor of Global Health

2013-present Member, Duke Cancer Institute

2013-present Director, Sociobehavioral Sciences in HIV Research Training Program

2020-present Senior Advisor, Duke Global Health Institute

**Publications:**

**1. Refereed journals:**

Bartlett JA, Gaillard RK, Joklik WK. Sequencing of supercoiled plasmid DNA. Biotechniques. 4:208-210, 1986.

Cohen JI, Bartlett JA, Corey GR. Extraintestinal Salmonellosis. Medicine. 66:349-388, 1987.

Bartlett JA, Joklik WK. The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1. Virology. 167:31-37, 1988.

Bartlett JA. HIV therapeutics: an emerging science. JAMA 260:3051-3052, 1988.

Weiner JR, Bartlett JA, Joklik WK. The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu2 and the major non-structural protein muNS, respectively. Virology. 169:293-304, 1989.

Shaunak S, Bartlett JA. Zidovudine: Clinical use and complications in treatment. AIDS Medical Report. 2:33-39, 1989.

Shaunak S, Bartlett JA. Zidovudine-induced neutropenia: Are we too cautious? Lancet. 2:91-92, 1989.

Drew RH, Weller S, Gallis HA, Walmer KA, Bartlett JA, Blum MR. Bioequivalence assessment of Retrovir syrup, solution and capsule formulations in HIV infected patients. Antimicrobial Agents and Chemotherapy. 33:1801-1803, 1989.

Tyler DS, Shaunak S, Bartlett JA, Inglehart JD. HIV-1 associated thrombocytopenia: The role of splenectomy. Annals of Surgery. 211:211-217, 1990.

Volberding P, Lagakos S, Koch M, Pettinelli C, Myers M, Booth D, Balfour H, Reichman R, Bartlett JA, Hirsch M, Murphy R, Hardy WD, Soeiro R, Fischl M, Bartlett JG, Merigan T, Hyslop N, Richman D, Valentine F, Corey L and the AIDS Clinical Trials Group. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. New England Journal of Medicine. 322:941-949, 1990.

Tyler D, Stanley D, Nastala C, Stine K, Austin A, Bartlett J, Lyerly H, Bolognesi D, Weinhold K. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Journal of Immunology. 144:3375-3384, 1990.

Telen MJ, Roberts KB, Bartlett JA. HIV-associated autoimmune hemolytic anemia: Report of a case and review of the literature. Journal of Acquired Immune Deficiency Syndromes. 3:933-937, 1990.

Shaunak S, Albright RE, Klotman ME, Henry SC, Bartlett JA, Hamilton JD. Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurological disease. Journal of Infectious Diseases. 161:1068-1072, 1990.

Ingram C, Bartlett JA. Simultaneous pneumococcal and pneumocystis pneumonia in patients with the acquired immune deficiency syndrome: Report of two cases. Southern Medical Journal. 83:1215-1217, 1990.

Cameron M, Bartlett J, Gallis H, Waskin H. Manifestations of pulmonary cryptococcosis in patients with acquired immune deficiency syndrome. Reviews of Infectious Diseases. 13:64-67, 1991.

Hersh E, Abrams D, Bartlett J, Brewton G, Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas J, Landesman S, Levine A, Marcel A, Peterson E, Whiteside M, Zahradnik J, Negron C, Boutitie F, Caraux J, Dupuy J, Salmi L. A randomized double-blind placebo-controlled multicenter study of sodium ditiocarb (diethyldithiocarbamate) therapy

in patients with ARC and AIDS. Journal of the American Medical Association. 265:1538-1544, 1991.

Shadduck PP, Weinberg JB, Haney AF, Bartlett JA, Langlois AJ, Bolognesi DP, Matthews TJ. Lack of enhancing effect of human anti-HIV-1 antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. Journal of Virology. 65:4309-4316, 1991.

Stine KC, Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold K. The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. Cellular Immunology. 136:165-172, 1991.

Chen C-H, Weinhold KJ, Bartlett JA, MacDougall MJ, Greenberg ML. CD8+ T-lymphocytes mediated inhibition of HIIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Research & Human Retroviruses. 9:1079-1086, 1993.

Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms in HIV-1 seropositive individuals. Antimicrobial Agents and Chemotherapy. 37:2449-2453, 1993.

Myers SA, Prose NS, Bartlett JA. Progress in the understanding of HIV infection: An overview. Journal of the American Academy of Dermatology. 29:1-21, 1993.

Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy. 38:799-804, 1994.

Volberding P, Lagakos S, Grimes J, Stein D, Balfour H, Dolin R, Bartlett J, Hirsch M, Phair J, Mitsuyasu R, Fischl M, Soeiro R and the AIDS Clinical Trial Group. The duration of zidovudine benefit in persons with asymptomatic HIV infection: Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. Journal of the American Medical Association. 272:437-442, 1994.

May DB, Drew R, Yedinak J, Bartlett JA. Effect of simultaneous didanosine(DDI) administration on itraconazole absorption in healthy volunteers. Pharmacotherapy. 14(5):509-513, 1994.

Bartlett JA. Early *versus* delayed zidovudine in the management of HIV infection. Expert Opinions in Investigational Drugs. 3(8):809-819, 1994.

Graham CS, Graham BG, Bartlett JA, Heald AE, Schiffman SS. Taste and smell losses in HIV infected patients. Physiology & Behavior. 58:287-294, 1995.

Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis G, Lalezari J, Bartlett JA, Steigbigel RT, Cohen J, Novak R, McMahon D, Fauci AS. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects down regulation of viral replication in lymphoid tissue. Proceedings of the National Academy of Sciences USA. 92:6017-6021, 1995.

Ferrari G, King K, Rathbun K, Packard M, Bartlett JA, Bolognesi D, Weinhold K. Interleukin 7 (IL-7) enhancement of antigen-driven activation/expansion of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte precursors (CTL). Clinical and Experimental Immunology 1995;101:239-248.

Jacobson MA, DeGruttola V, Reddy M, Ardvino J-M, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, Soiero R, Volberding P. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS 1995;9:727-734.

Anstey N, Packard M, Stewart L, Graney W, Bartlett JA. Open-label titration study of the safety of RMP-7 in patients with the acquired immune deficiency syndrome. International Journal of Antimicrobial Agents

1996;6:183-187.

Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS. Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on viral load in peripheral blood and lymph nodes. Journal of Infectious Diseases. 173:849-856, 1996.

Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS. 10:263-268, 1996.

Heald AE, Hsyu P, Yuen G, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in HIV-infected patients with renal dysfunction. Antimicrobial Agents and Chemotherapy 40(6):1514-1519, 1996.

Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC*, et al*. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996,125:161-172.

Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S*, et al.* HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. *AIDS* 1996,10:859-865.

Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). International Journal of STDs and AIDS. 7:337-346, 1996.

Riddler SA, Wang LH, Bartlett JA, Savina PM, Packard MV, McMahon DK, Blum MR, Dunn JA, Elkins MM, Mellors JW. Safety and phamacokinetics of 5-chloro-2',3'-dideoxy-3'fluorouridine (935U83) following oral administration of escalating single doses in HIV-infected adults. Antimicrobial Agents and Chemotherapy. 40(12):2842-2847, 1996.

Gottfredsson M, Oury T, Bernstein C, Carpenter C, Bartlett JA. Lymphoma of the pituitary gland: An unusual presentation of central nervous system lymphoma in AIDS. American Journal of Medicine. 5:563-564, 1996.

Phillips AN, Eron J, Bartlett JA, Gilbert C, Johnson J, Keller A, Hill AM, and the North American Lamivudine HIV Working Group. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. AIDS. 11(2):169-175, 1997.

Staszewski S, Hill AM, Bartlett JA, Eron JJ, Katlama C, Johnson J, Sawyer W, McDade H. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS. 11:477-483, 1997.

Bartlett JA, Hullette C. Central nervous system pneumocysostis in the acquired immune deficiency syndrome. Clinical Infectious Diseases. 25:82-85, 1997.

Ferrari G, Berend C, Ottinger J, Dodge R, Bartlett J, Toso J, Moody D, Tartaglia J, Cox W, Paoletti E, Weinhold K. Replication -defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiemcy virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy. Blood, (90) 6; 2406-2416, 1997.

Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA and Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: A prospective, multicenter trial. Journal of Immune Deficiency Syndromes and Human Retrovirology. 16:100-107, 1997.

Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: A potential strategy for reduction of virus-infected cellular reservoirs. Journal of Surgical Research 79:115-120 1998.

Bartlett JA, Berry P, Bockman W, Johnson J, Quinn J, Graham S, DeMasi R, Alexander WJ. A placebo controlled trial of ranitidine in patients with early HIV infection. Journal of Infectious Diseases 1998;177:231-234.

Bartlett JA, Berend C, Ottinger J, Tyler D, Petroni G, Petinelli C, Weinhold KJ. Co-administration of zidovudine and interleukin-2 increases absolute CD4+ cells in subjects with Walter Reed stage 2 HIV infection: Results of ACTG protocol 042. Journal of Infectious Diseases, 1998;178:1170-1173.

Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS 1998,12:1291-1300.

Bartlett JA. Strategies of antiretroviral therapy in adults. The Oncologist 1998;3:111-118.

Bartlett JA, DeMasi R, Dawson D, Hill A.Variability in the repeated consecutive measurements of plasma HIV RNA in persons on stable nucleoside reverse transcriptase inhibitor or no therapy. Journal of Infectious Disease 1998;178:1803-1805.

Haynes BF, Hale L, Weinhold K, Patel D, Liao HX, Bressler P, Jones D, Demarest J, Gebhard-Mitchell K, Haase, Bartlett JA. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. Journal of Clinical Investigation 103:453-460, 1999.

Moore KHP, Yuen GY, Hussey EK, Pakes GE, Eron JJ, Bartlett JA. Population pharmacokinetics of lamivudine in adult HIV-infected patients enrolled in two phase III clinical trials. Antimicrobial Agents & Chemotherapy 43(12): 1999.

Markert ML, Hicks CB, Bartlett JA, Harmon JL, Hale LP, Greenberg ML, et al. Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses 2000,16:403-413.

Nelson CG, Iler MA, Woods CW, Bartlett JA, Fowler VG. Meningococcemia in a patient co-infected with Hepatitis C virus and HIV. Emerging Infectious Diseases 6(6):646-648, 2000.

Human Immunodefciency Virus Type 1 RNA level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis. AIDS Research and Human Retroviruses 16(12):2000, pp.1123-1133.

Keitz SA, Box TL, Homan RK, Bartlett JA, Oddone EZ. Primary care for patients infected with human immunodeficiency virus. Results of a randomized controlled trial. Journal of General Internal Medicine 16:1-10, 2001.

Wellons M, Ottinger J, Weinhold K, Gryszowka V, Sanders L, Edwards L, Gooding M, Thomasch, Bartlett JA. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. Journal of Infectious Diseases 183:1522-1525, 2001.

Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 15:1369-1377, 2001.

Markert L, Africa P, Alvarez-McLeod, Sempowski G, Hale L, Horvatinovich J, Weinhold K, Bartlett JA, D’Amico T, Haynes B. Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. AIDS 17(17):1635-1643, 2001.

Ortiz G, Wellons M, Brancato J, Vo H, Zinn R, Clarkson D, van Loon K, Bonhoeffer S, Miralles G, Montefiori D, Bartlett JA, Nixon D. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. PNAS 98(23):13288-13293, 2001.

Szczech L, Gange S, van der Horst C, Bartlett JA, Young M, Cohen M, Anastos K, Klassen P, Svetkey L. Predictors of proteinuria and renal failure among women with HIV infection. Kidney International 61:195, 2002.

Bartlett JA, Miralles GD, Sevin A, Silberman M, Pruitt S, Ottinger J, Gryszowka, Fiscus S, Bucy P and the ACTG 380 Study Team. Addition of Cyclophosphamide to Antiretroviral Therapy Does Not Diminish the Cellular Reservoir in HIV-infected Persons. AIDS Res & Human Retroviruses, 18(8):535-43, 2002.

Bartlett JA. Addressing the Challenges of Adherence. J Acquired Immune Deficiency Syndromes 29:S2-S10, 2002.

Wellons M, Sanders L, Edwards L, Bartlett JA, Heald A, Schmader K. HIV Infection: Treatment Outcomes in Older and Younger Adults. J Am Geriatrics Society, 50(4):603-607, 2002.

Siraj DS, Bartlett JA, Hyslop N. An Infected Laceration. Infections in Medicine, 19:63-65, 2002.

Szczech L, Edwards L, Sanders L, van der Horst C, Bartlett JA, Heald A, Svetkey L. Protease inhibitors are associated with a slowed progression of HIV-associated renal diseases. Clinical Nephrology 57(5):336-41, 2002.

Schweighardt B, Ortiz G, Grant R, Wellons M, Miralles D, Kostrikis L, Bartlett JA, Nixon D. Emergence of drug resistant HIV-1 variants in subjects undergoing structured treatment interruptions. AIDS 16(17):2342-4, 2002.

Bartlett JA, Tebas P, Bassett R, Huang W, Kuritzkes D, Reisler R, Loyack N, Robison K and the ACTG A5064 Team. Early Intensification with Aabacavir in Subjects at High Risk for Incomplete Viral Suppression. Antiviral Therapy 8:361-363; 2003.

Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, 2nd, Schweighardt B, et al. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr 34:475-481,2003.

Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 189:1075-1083, 2004.

Ole-Nguyaine S, Crump JA, Kibiki GS, Kiang K, Taylor J, Schimana W, et al. HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. Ann Trop Med Parasitol 98:171-179, 2004.

Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M, et al. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS 18:1203-1206, 2004.

Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Definition of proteinuria among women with HIV infection. Kidney Int 65:1519, 2004.

Chu HY, Crump JA, Ostermann J, Oenga RB, Itemba DK, Mgonja A, et al. Sociodemographic and clinical characteristics of clients presenting for HIV voluntary counselling and testing in Moshi, Tanzania. Int J STD AIDS 16:691-696, 2005.

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191:825-829, 2005.

Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, Elston R, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr 41:323-331, 2006.

Thielman NM, Chu HY, Ostermann J, Itemba DK, Mgonja A, Mtweve S, et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health 96:114-119, 2006.

Myers S, Selim A, McDaniel M, Hall R, Zhang Y, Bartlett JA, True A. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antiviral Therapy 11:935-939, 2006

Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, Griffith S, Irlbeck D, Shaefer MS for the CLASS Team. Long Term Results of Initial Therapy with Abacavir and Lamivudine Combined with Efavirenz, Amprenavir/Ritonavir or Stavudine. J Acquir Immune Defic Syndr 43(3): 284-292, 2006

Bartlett JA, Fath MJ, DeMasi R, Hermes A, Quinn J, Mondou E, Rousseau Franck. An Updated Systematic Overview of Triple Combination Therapy in Antiretroviral-Naïve HIV-Infected Adults. AIDS, 20:2051-2064, 2006

Haas DW, Bartlett JA, Anderson JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB. Pharmacogenetics of Nevirapine-associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration. Clinical Infectious Diseases 43: 783-786, 2006

Fangping C, Chen H, Hicks C, Bartlett J, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nature Methods 4:123-125, 2007

Landman KZ, Thielman NM, Mgonja A, Shao HJ, Itemba DK, Ndosi EM, Chu HY, McNeill JD, Shao JF, Bartlett JA, Crump JA. Risk factors for low HIV treatment literacy among clients presenting for voluntary testing and counseling in Moshi, Tanzania. J Int Assoc Physicians AIDS Care 6: 24-26, 2007.

Riddler S, Jiang H, Tenorio A, Huang H, Kuritzkes D, Acosta E, Landay A, Bastow B, Haas D, Tashima K, Jain M, Deeks S, Bartlett JA. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study 5115. Antiviral Therapy 12:531-541, 2007.

Morpeth S, Crump J, Shao H, Ramadhani H, Kisenge P, Moylan C, Naggie S, Caram LB, Landman K, Sam N, Itemba D, Shao J, Bartlett J, Thielman N. Predicting CD4 Lymphocyte Count < 200 cells/mm 3 in an HIV-1-Infected African Population. AIDS Research & Human Retroviruses 23:1230-1236, 2007.

Ramadhani H, Thielman N, Landman K, Ndosi E, Gao F, Kircherr J, Shah R, Shao H, Morpeth S, McNeill J, Shao J, Bartlett J, Crump J. Predictors of incomplete adherence, virologic failure, and viral drug resistance among HIV-1 infected persons receiving antiretroviral therapy in Tanzania. Clin Inf Dis: 45:1492-1498, 2007.

Anderson A, Kosinski A, Bartlett J. Declining CD4+ T-cell count during suppressed or low level viremia in patients with HIV infection. Antiviral Therapy; 12:1041-1048, 2007.

Bartlett JA, Chen S-S, Quinn J. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: Results of a systematic overview. HIV Clinical Trials; 4:221-226, 2007.

Morpeth S, Thielman N, Ramadhani H, Hamilton J, Ostermann J, Kisenge P, Shao H, Reller LB, Itemba D, Sam N, Bartlett J, Shao J, Crump J. Effect of trimethoprim/sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Eschericia coli in HIV-infected patients in Tanzania. J Acquir Immune Defic Syndr; 47:585-591, 2008.

Landman K, Ostermann J, Crump J, Mgonja A, Mayhood M, Itemba D, Tribble A, Ndosi E, Chu H, Shao J, Bartlett J, Thielman N. Gender differences in the risk of HIV infection among persons reporting abstinence, monogamy, and multiple sexual partners in northern Tanzania. PLoS One; 3:e3705, 2008.

Seshadri C, Uiso LO, Ostermann J, Diefenthal H, Shao HJ, Chu HY, Asmuth DM, Thielman NM, Bartlett JA, Crump JA. Low sensitivity of T-cell based detection of tuberculosis among HIV co-infected Tanzanian inpatients. East African Med J 2008; 85: 443-449.

Crump JA, van Ingen J, Morrissey AB, Boeree MJ, Mavura DR, Swai B, Thielman NM, Bartlett JA, Grossman H, Maro VP, van Soolingen D. Invasive disease caused by nontuberculous mycobacteria, Tanzania. Emerg Infect Dis 2009; 15: 53-5.

Tenorio A, Jiang H, Bastow B, Bartlett J, Deeks S, Landay A, Riddler S. Delaying a treatment switch in antiretroviral-treated HIV-1 infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Research & Human Retroviruses, 2009; 25: 135-139.

Tillekeratne G, Thielman N, Kiwera R, Chu H, Kaale L, Morpeth S, Ostermann J, Mtweve S, Shao J, Bartlett J, Crump J. High morbidity and mortality in a cohort of HIV-infected adults receiving community home-based care in the Kilimanjaro region, Tanzania, 2003-2005. Ann Trop Med Parasitol, 2009; 103:263-73.

Tribble A, Hamilton C, Crump J, Mgonja A, Mtalo A, Ndanu E, Itemba D, Landman K, Ndosi E, Shao J, Bartlett J, Thielman N. Missed Opportunities for Diagnosis of TB-HIV/AIDS Co-infection in Moshi, Tanzania. Int J TB and Lung Dis 2009; 7:1260-1266.

Bartlett J, Hornberger J, Sherwade A, Bhor, M, Rajagopalan R. Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings. J Int Assoc Physicians in AIDS Care 2009; 8:253-268.

Mayhood M, Ostermann J, Crump J, Tribble A, Itemba D, Mgonja A, Mtalo A, Bartlett J, Shao J, Schimana W, Thielman N. Characteristics of HIV voluntary testing and counseling clients before and during care and treatment scale-up in Moshi, Tanzania. J Acquired Immun Defic Syndr 2009; 52:648-654.

Bartlett J, Shao J. Success, challenges and limitations of antiretroviral therapy in resource-limited settings. The Lancet Infectious Diseases 2009; 9:637-649.

Lofgren S, Morrissey A, Chevalier C, Malabeja A, Edmonds S, Amos B, Sifuna D, Msuya E, von Seidlein L, Schimana W, Stevens W, Bartlett J, Shao J, Crump J. Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote health care facilities. AIDS 2009; 23:2459-2466.

Shao H, Crump J, Ramadhani H, Uiso L, Ole-Nguyaine S, Moon A, Kiwera R, Shao J, Bartlett J, Thielman N. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients co-infected with HIV and tuberculosis in Tanzania. AIDS Research & Human Retroviruses 2009; 25:1277-1285.

#### SzczechL, MenezesP, QuinlivanEB, van der HorstC, BartlettJ, and SvetkeyL. Microalbuminuria predicts overt proteinuria among patients with HIV infection. HIV Medicine 2009; 11: 419-426.

Emmett S, Cunningham C, Mmbaga B, Kinabo G, Schimana W, Swai M, Bartlett J, Crump J, Reddy E. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: A cross-sectional study. J Acquired Immune Def Syndr 2010; 54: 368-376.

Buchanan A, Muro F, Gratz J, Crump J, Musyoka A, Sichangi, M, Morrissey A, M'rimberia J, Njau B, Msuya L, Bartlett J, Cunningham C. Establishment of hematologic and immunologic reference values for healthy Tanzanian children in the Kilimanjaro region. Tropical Medicine and International Health 2010; 15:1011-1021.

Crump J, Ramadhani H, Morrissey A, Saganda W, Mwako M, Yang L-Y, Chow S-C, Morpeth S, Reyburn H, Njau B, Shaw A, Diefenthal H, Shao J, Bartlett J, Maro V. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clinical Infectious Diseases 2011; 52:341-348.

Ostermann J, Reddy E, Shorter M, Muiruri C, Mtalo A, Itemba D, Njau B, Bartlett J, Crump J, Thielman N. Who tests, who doesn’t, and why? Uptake of mobile HIV counseling and testing in the Kilimanjaro region of Tanzania. PLoS One 2011; 6:e16488.

Waters R, Ostermann J, Reeves T, Masnick M, Thielman N, Bartlett J, Crump J. A cost-effectiveness analysis of alternative HIV retesting strategies in sub-Saharan Africa. J Acquired Immune Def Syndr 2011; 56:443-452.

Crump JA, Ramadhani HO, Morrissey AB, Msuya LJ, Yang L-Y, Chow S-C, Morpeth SC, Reyburn H, Njau BN, Shaw AV, Diefenthal HC, Bartlett JA, Shao JF, Schimana W, Cunningham CK, Kinabo GD. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. Trop Med Int Health 2011; 16:830-837.

Prabhu M, Nicholson W, Roche A, Kersh G, Fitzpatrick K, Oliver L, Massung R, Morrissey A, Bartlett J, Onyango J, Maro V, Kinabo G, Saganda W, Crump J. Q fever, spotted fever group and typhus group rickettsioses among hospitalized febrile patients in northern Tanzania 2007-2008. Clinical Infectious Diseases 2011, 53:e8-15.

Biggs H, Bui D, Galloway R, Stoddard R, Shadomy S, Morrissey A, Bartlett J, Onyango J, Maro V, Kinabo G. Saganda W, Crump J. Leptospirosis among hospitalized patients with febrile illness in northern Tanzania. Am J Public Health 2011, 85:275-281.

Vidal A, Murphy S, Hernandez B, Vasquez B, Bartlett J, Oneko O, Overcash F, Smith J, Obure J, Hoyo C. Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. Infectious Agents and Cancer 2011, 6:20

Kolman M, Decoster M, Proeschold-Bell RJ, Ankeny G, Bartlett J, Sena A. The impact of HIV infections, sexually transmitted diseases and viral hepatitis in Durham County, North Carolina: A call for coordinated and integrated services. NC Medical Journal 2012, 72:439-446.

Hertz J, Munishi O, Ooi EE, Shiqin H, Yan LW, Chow A, Morrissey A, Bartlett J, Onyango J, Maro V, Kinabo G, Saganda W, Gubler D, Crump J. Chikungunya and dengue fever among febrile hospitalized patients in northern Tanzania. Am J Trop Med Hyg 2012, 86:171-177.

Bartlett J, Ribaudo H, Wallis C, Aga E, Katzenstein D, Stevens W, Norton M, Klingman K, Housseinipour M, Crump J, Supparatpinyo K, Badal-Faesen S, Kallungal B, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012, 26:1345-1354.

Crump J, Ramadhani H, Morrissey A, Saganda W, Mwako M, Yang L-Y, Chow S-C, Njau B, Mushi G, Maro V, Reller LB, Bartlett J. Bacteremic disseminated tuberculosis in sub-Saharan Africa: a prospective cohort study. Clin Inf Dis 2012; 55:242-250.

Bouley A, Biggs H, Stoddard R, Morrissey A, Bartlett J, Afwamba I, Maro V, Kinabo G, Saganda W, Cleaveland S, Crump J. Brucellosis among hospitalized febrile patients in northern Tanzania. Am J Trop Med & Hyg 2012; 87:1105-1011.

Nye M, Hoyo C, Huang Z, Vidal A, Wang F, Overcash F, Smith J, Vasquez B, Hernandez B, Swai B, Oneko O, Mlay P, Obure J, Gammon M, Bartlett J, Murphy S. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. PLoS One 2013; 8:e56325.

Zullig L, Muiruri C, Abernethy A, Weiner B, Bartlett J, Oneko O, Zafar S. Cancer registration needs assessment at a tertiary medical center in Kilimanjaro, Tanzania. World Health & Population 2013; 14:12-23.

Phillips E, Bartlett J, Sanne I, Lederman M, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal S, Haas D. Associations between HLA-DRB1\*0102, HLA-B\*5801 and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquired Immune Def Syndr 2013; 62:e55-57.

Crump J, Morrissey A, Nicholson W, Galloway R, Stoddard R, Ooi EE, Maro V, Sanganda W, Kinabo G, Bartlett J. Etiology of non-malaria fever among hospitalized patients in Northern Tanzania. PLoS Neg Trop Dis 2013; 7:e2324.

Fiorillo S, Diefenthal H, Goodman P, Ramadhani H, Njau B, Morrissey A, Mwako M, Bartlett J, Shao J, Saganda W, Kinabo G, Maro V, Crump J. Chest radiograph abnormalities and their role for predicting etiology of febrile illness among inpatients in Moshi, Tanzania. Clinical Radiology, 2013; 68:1039-46.

Mavura D, Masenga EJ, Minja E, Grossmann H, Crump J, Bartlett J. Initiation of antiretroviral therapy in HIV-infected adults with cutaneous manifestations in northern Tanzania. Internat Journ Dermatology; 2014: doi: 10.1111/ijd.12563.

Killewo L, Lisasi E, Kapanda G, Tibyampansha D. Ibrahim G, Kulanga A, Muiruri C, Fadhili N, Wiener D, Wood A, Kessi E, Mteta K, Ntabaye M, Bartlett J. Introduction of a learning management system at the Kilimanjaro Christian Medical University College. African Journal of Health Professions Education, 2014;6:37-40.

Buchanan A, Dow D, Massambu C, Nyombi B, Shayo A, Musoke R, Feng S, Bartlett J, Cunningham C, Schimana W. Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania. PLoS One, 2014; 9:e88679.

Zullig LL, Vanderburg SB, Muiruri C, Abernethy A, Weiner BJ, Bartlett JA, Oneko O, Lisasi E, Munishi OM, Zafar SY. Sustainability of cancer registration in the Kilimanjaro region of Tanzania- A qualitative assessment. World Health & Population, 2014;15:21-30.

Nyindo M, Kitau J, Lisasi E, Kapanda G, Matowo J, Francis P, Bartlett J. Introduction of team-based learning (TBL) at Kilimanjaro Christian Medical University College: Experience with the Ectoparasites Module. Medical Teacher, 2014;36:308-313.

Harmon JL, Collins-Ogle M, Bartlett J, Thompson J, Barroso J. Integrating routine HIV screening into a primary care setting in rural North Carolina. Journ Am Assoc Nurses in AIDS Care, 2014;25:70-82.

Reddy E, Njau B, Morpeth S, Lancaster K, Tribble A, Maro V, Msuya L, Morrissey A, Kibiki G, Thielman N, Cunningham C, Schimana W, Shao J, Chow S-C, Stout J, Crump J, Bartlett J, Hamilton C. High early morality in a randomized controlled of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in northern Tanzania. BMC Infectious Diseases, 2014:14:89.

Bartz S, Mody A, Kiyimba T, Hornick C, Bain J, Muehlbauer M, Kiboneka E, Stevens R, Bartlett J, St. Peter J, Newgard C, Freemark M. Severe acute malnutrition in childhood: metabolic and hormonal status at presentation, response to treatment, and predictors of mortality. Journ of Clin Endocrin Metabol; 2014: http://dx.doi.org?\/10.1210/jc.2013-4018.

Wallis C, Aga E, Ribaudo H, Saravanan S, Norton M, Klingman K, Stevens W, Kumarasamy N, Bartlett J, Katzenstein D. Drug susceptibility and resistance mutations after first-line failure in resource-limited settings. Clin Inf Dis, 2014; 59: 706-715.

De Boer C, Niyonzima N, Orem J, Bartlett J, Zafar SY. Prognosis and delay of diagnosis among Kaposi’s sarcoma patients in Uganda: A cross-sectional study. Infect Agents and Cancer, 2014; 9:17.

Lisasi E, Kulanga A, Muiruri C, Killewo L, Fadhili N, Mimano L, Kapanda G, Tibyampansha D, Ibrahim G, Nyindo M, Mteta K, Kessi E, Ntabaye M, Bartlett J. Modernizing and transforming medical education at the Kilimanjaro Christian Medical University College. Academic Medicine, 2014; 89:S60-64.

Mody A, Bartz S, Kiyimba T, Bain J, Muehlbauer M, Kiboneka E, Stevens R, St. Peter J, Newgard C, Bartlett J, Freemark M. Effects of HIV infection on metabolic and hormonal status in children with severe acute malnutrition. PLoS One; 2014: 9:e102233.

Ramadhani H, Bartlett J, Thielman N, Pence B, Kimani S, Maro V, Mwako M, Masaki L, Mmbando C, Minja M, Lirhunde A, Miller W. Association of first-line antiretroviral therapy adherence with adherence to second-line antiretroviral therapy among HIV-infected patients in Tanzania. Open Forum Infectious Diseases, 2014; doi:10.1093/ofid/ofu079.

Rubach M, Maro V, Bartlett J, Crump J. Evaluation of integrated management of adolescent and adult illness district clinician manual empiric antibiotic therapy recommendations for severe infections in northern Tanzania. Am J Trop Med Hyg, 2015; 92:454-462.

Kumarasamy N, Aga E, Ribaudo H, Wallis C, Katzenstein D, Stevens W, Norton M, Klingman K, Bartlett J. Lopinavir/ritonavir monotherapy after virologic failure of first-line NNRTI-containing antiretroviral therapy in resource-limited settings: Week 104 analysis of ACTG A5230. Clin Inf Dis 2015; 60:1550-1558.

Vidal A, Skaar D, Maquire R, Dodor S, Musselwhite L, Bartlett J, Oneko O, Obure J, Mlay P, Murphy S, Hoyo C. IL-10, IL-15, IL-17 and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV 16/18 genotypes. Infectious Agents and Cancer 2015; 10:10; doi:10.1186/s13027-015-0005-1

Mimano L, Ferrari G, Kapanda G, Lisasi E, Kulanga A, Nyombi B, Muiruri C, Kessi E, Bartlett J, Ntabaye M. Student perceptions on the introduction of training in diagnostic laboratory techniques in an African school of medicine. MedEdPublish 2015: <http://dx.doi.org/10.15694/mep.2015.005.0008>

Derache A, Wallis C, Vardanabhuti S, Bartlett J, Katzenstein D. Phenotype, genotype and drug resistance in subtype C HIV-1 infection. Journ Inf Dis 2016; 213:250-256.

Ramadhani H, Bartlett J, Thielman N, Pence B, Kimani S, Maro V, Mwako M, Masaki L, Mmbando E, Miller W. The effect of switching to second-line antiretroviral therapy on the risk of opportunistic infections among patients infected with human immunodeficiency virus in northern Tanzania. Open Forum Infect Dis 2016; Jan 29;3(1):ofw018. doi: 10.1093/ofid/ofw018. eCollection 2016 Jan.

Kapanda G, Muiruri C, Kulanga A, Tarimo C, Lisasi E, Mimano L, Mteta K, Bartlett J. Enhancing future acceptance of rural placement in Tanzania through peripheral hospital rotations for medical students. BMC Medical Education; 16:51doi**:** 10.1186/s12909-016-0582-8.

Zullig L, Schroeder K, Nyindo P, Namwai T, Silayo E, Moomba A, Munishi M, Karia F, Muiruri C, Bartlett J, Maro V, Zafar Y. Validation and quality assessment of the Kilimanjaro Cancer Registry. Journ Global Oncology; doi: 10.1200/JGO.2015.002873.

Borges A, Lundh A, Tendal B, Bartlett J, Clumeck N, Costagliola D, Daar E, Echeverria P, Gisslen M, Huedo-Medina T, Hughes M, Hullseik K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur R, Maggiolo F, Matteeli A, Miro J, Oka S, Petoumenos K, Puls R, Riddler S, Sax P, Sierra-Madero J, Torti C, Lundgren J. Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based regimens for the initial treatment of HIV infection: a systematic review and meta-analysis of randomized trials. Clin Inf Dis 2016; 63:268-280.

Ramadhani H, Muiruri C, Maro V, Omondi M, Mushi J, Lirhunde L, Bartlett J. Association of knowledge on ART line of treatment, scarcity of treatment options and adherence. BMC Health Services Research 2016; 16:265  
DOI: 10.1186/s12913-016-1483-6.

Vardhanbhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis C. Human immunodeficiency virus-1 sequence changes and drug resistance mutations among virologic failures of lopinavir/ritonavir monotherapy: AIDS Clinical Trials Group Protocol A5230. Open Forum Inf Dis 2016; 3 (3): ofw154 doi: 10.1093/ofid/ofw154

Msoka T, Van Guilder G, Smulders Y, van Furth M, Bartlett J, van Agtmael M. Antiretroviral treatment and time since HIV-1 diagnosis are associated with large artery stiffness in sub-Saharan African HIV-1 patients. Artery Research 2016; 16:34-41.

Matoga M, Hosseinipour M, Aga E, Ribaudo H, Bartlett J, Kumarasamy N, Hughes M and the ACTG A5230 Study Team. Hyperlipidemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. Antiviral Therapy 2016; **doi:** 10.3851/IMP3101.

Ramadhani H, Muiruri C, Maro V, Nyombi B, Omondi M, Mushi J, Lirhunde E, Bartlett J. Patient-initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. AIDS and Behavior 2017; DOI 10.1007/s10461-017-1721-x.

Tibyampansha D, Ibrahim G, Kapanda G, Tarimo C, Minja A, Kulanga A, Muiruri C, Mteta K, Kessi E, Bartlett J. Implementation of a learning management system for medical students: A case study of Kilimanjaro Christian Medical University College. MedEdPublish 2017: **DOI:**<https://doi.org/10.15694/mep.2017.000050>

Dow D, Schimana W, Nyombi B, Mmbaga B, Shayo A, Bartlett J, Massambu C, Kifaro E, Turner E, DeMarco T, Cai F, Cunningham C, Buchanan A. HIV resistance with correlation to PMTCT regimen in HIV-infected infants in northern Tanzania. AIDS Res Human Retroviruses 2017; DOI: 10.1089/AID.2017.0025.

Paul D, Neely M, Clement M, Riley I, Phelan M, Huang Y, Al-Hegelan D, Lucas J, Murdoch D, Bartlett J, McKellar M, Que L. Development and validation of an electronic medical record (EMR)-based computed phenotype of HIV-1 infection. Journ Amer Medical Informatics Assoc 2017; ocx061, <https://doi.org/10.1093/jamia/ocx061>.

Bartlett J, Cao S, Mmbaga B, Xu Q, Merson M, Kramer R. Strengthening an Academic Global Health Network Through a Partnership Conference. Annals of Global Health 2017; <https://doi.org/10.1016/j.aogh.2017.08.002>.

Semvua S, Orrell C, Mmbaga B, Semvua H, Bartlett J, Boulle A. Predictors of non-adherence to antiretroviral therapy among HIV-infected patients in northern Tanzania. PLoS One 2017 12(12): e0189460. <https://doi/org/10.1371/journal.pone.0189460>

Tarimo C, Kapanda G, Muiruri C, Kulanga A, Lisasi E, Mteta K, Kessi E, Mogella D, Maro V, Temu R, Mimano L, Bartlett J. Enhancing the quality of clinical clerkships in a resource-limited setting medical school in Northern Tanzania: A three-year experience. Annals of Global Health 2018; 84:129-138.

Corrigan K, Wall K, Bartlett J, Suneja G. Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining malignancies. Cancer 2018; DOI: 10.1002/cncr.31838.

Msoka T, Van Guilder G, Smulders Y, van Furth M, Bartlett J, van Agtmael M. Association of HIV infection, antiretroviral treatment and metabolic syndrome with large artery stiffness: a cross-sectional study. BMC Infectious Diseases 2018; 18:708.

Irira M, Ngocho J, Youze J, Shayo I, Komba V, Minja L, Karia F, Bartlett J, Mmbaga B. Prevalence and outcome of HIV-associated malignancies among HIV-infected children enrolled into care at Kilimanjaro Christian Medical Center 2006 to 2014: A hospital-based retrospective analytical study. J Pediatr Hematol Oncol. 2018; doi: 10.1097/MPH.0000000000001389.

Munishi O, Mmbaga B, Mchome B, Mangi G, McKenzie F, Zullig L, Bartlett J, Mapunda O, Nyindo P, Namwai T, Muiruri C, Mtaresi F, Karia F, McCormack V. Awareness of cancer risk factors and warning symptoms in Northern Tanzania: A cross-sectional survey in the general population and in people living with HIV. Journal of Cancer Education 2019; https://doi.org/10.1007/s13187-019-01513-6.

.

Msoka T, Van Guilder G, van Furth M, Smulders Y, Meek S, Bartlett J, Vissoci J, van Agtmael M. The effect of HIV infection, antiretroviral therapy on carotid intima-media thickness: A systematic review and meta-analysis. Life Sciences 2019; [https://doi.org/10.1016/j.lfs.2019.116851](https://urldefense.proofpoint.com/v2/url?u=https-3A__doi.org_10.1016_j.lfs.2019.116851&d=DwMFaQ&c=imBPVzF25OnBgGmVOlcsiEgHoG1i6YHLR0Sj_gZ4adc&r=mz_pzvCUxtKUbyykxt7ewnxY4A1_csX_Ku0G_pp37eM&m=SEQlSQ5BLvMRblh_CJa3xDf3pc8Fjw4MVYmn169hbHg&s=EO_EKZ4rkI493nqIByEZjkOq7afu7YtGR_52ZM9V69M&e=)

Hertz JT, Sakita FM, Limkakeng AT, Mmbaga BT, Appiah LT, Bartlett JA, Galson SW. The burden of acute coronary syndrome, heart failure, and stroke among emergency department admissions in Tanzania: A retrospective observational study. Afr J Emerg Med. 2019 Dec;9(4):180-184. doi: 10.1016/j.afjem.2019.07.001. Epub 2019 Aug 8.

Hertz J, Sakita F, Kweka G, Loring Z, Thielman N, Temu G, Bartlett J. Health care seeking behavior, barriers to care, and predictors of symptom improvement among patients with cardiovascular disease in northern Tanzania. International Health 2019; <https://doi.org/10.1093/inthealth/ihz095>.

Muiruri C, Swai S, Ramadhani H, Knettel B, Mahande M, Msuya S, Bartlett J. Individual and partner characteristics associated with HIV testing and counseling among individuals 50 years or older in Tanzania. Int Journ STD AIDS 2019; DOI: 10.1177/0956462419874990.

Muiruri C, Jazowski S, Semvua S, Karia F, Knettel B, Zullig L, Ramadhani H, Mmbaga B, Bartlett J, Bosworth H. Does antiretroviral packaging matter? Perceptions and preferences of antiretroviral packaging for people living with HIV in Northern Tanzania. Patient Preference and Adherence 2020; 14:153-161.

Hertz J, Sakita F, Kweka G, Limkakeng A, Galson S, Ye J, Tarimo T, Temu G, Thielman N, Bettger J, Bartlett J, Bloomfield G. Acute myocardial infarction under-diagnosis and mortality among emergency department patients in northern Tanzania: a prospective observational study. American Heart Journal 2020: 226:214-221.

Mremi A, Mswima J, Mlay M, Bartholomew H, Alloyce J, Mmbaga B, Bartlett J. Cancer spectrum in HIV-infected patients: A zonal hospital experience. Cancer Treatment and Research Communications 2020; [https://doi.org/10.1016/j.ctarc.2020.100213](https://doi.org/10.1016/j.ctarc.2020.100213" \o "Persistent link using digital object identifier" \t "_blank)

Qureshi N, Mufarrih S, Bloomfield G, Tariq W, Almas A, Mokdad A, Bartlett J, Nisar I, Siddiqi S, Bhutta Z, Mark D, Douglas P, Samad Z. Disparities in cardiovascular research output and disease outcomes among high, middle and low income countries- An analysis of global cardiovascular publications over the last decade (2008-2017). Global Heart, in press.

Murray M, Ibrahim G, Tarimo C,Park L, Msuka G, Kapanda G, Kulanga A, Muiruri C, Bartlett J. Association between e-learning system usage and medical student academic performance at the Kilimanjaro Christian Medical University College in Moshi, Tanzania. MedED Publish 2020; <https://doi.org/10.15694/mep.2020.000278.1>

.

**2. Chapters in books:**

Bartlett JA and Perfect JR. The acquired immune deficiency syndrome. Medicine and Pediatrics; edited by James Crapo: Hanley and Belfus. 1987.Initiation of antiretroviral therapy in HIV-infected adults

McKinney RM, Bartlett JA and Frothingham T. Pediatric infectious diseases. Medicine and Pediatrics; edited by James Crapo: Hanley and Belfus. 1987.

Lyerly HK and Bartlett JA. Thoracic manifestations in the immunocompromised host. Gibbons’ Surgery of the Chest; edited by David Sabiston and Frank Spencer: WB Saunders Company. 1989.

Bartlett JA. Chronic management and counseling for persons with HIV infection. Cecil=s Textbook of Medicine; edited by Lloyd Smith, Claude Bennett, and James Wyngarden. 1991.

Bartlett JA, Gallis HA, Shipp KW, Nabors KL. Diagnosis and treatment of the patient with HIV infection. Care and

Management of Patients with HIV Infection; edited by John A. Bartlett: Clean Data Publishing Co., 1993.

Lyerly HK, DiMiao M and Bartlett JA. Thoracic manifestations in the immunocompromised host. Gibbon=s Surgery of the Chest; edited by David Sabiston and Frank Spencer: WB Saunders Company 1994.

Bartlett JA. Chronic management and counseling for persons with HIV infection. Cecil’s Textbook of Medicine;

edited by Claude Bennett. 1994.

Bartlett JA. Antiretroviral therapy. Caring for Persons with HIV Infection; edited by John A. Bartlett: Clean Data

Publishing Co., 1995.

Miralles GD, Bartlett JA. Virology and pathogenesis of HIV. Caring for Persons with HIV Infection; edited by John A. Bartlett: Clean Data Publishing Co., 1997.

Bartlett JA. Zalcitabine. AIDS Therapy; edited by Raphael Dolin, Henry Masur and Michael Saag: Churchill Livingstone, 1997.

Bartlett JA. Management and counseling for persons with HIV infection. Cecil’s Textbook of Medicine; edited by Lee Goldman and Claude Bennett. 1999.

Itani S and Bartlett JA. Strategies of Antiretroviral Therapy in Adults. Urologic Clinics of North America 26(4):809-820, *ix-x*, 1999.

Bartlett JA. Zalcitabine. AIDS Therapy; edited by Raphael Dolin, Henry Masur and Michael Saag: Churchill Livingstone, 2002.

Wellons MF, Bartlett JA. Emitricitabine. AIDS Therapy, edited by Raphael Dolin, Henry Masur and Michael Saag:

Churchill Livingstone, 2002.

Bartlett JA. Zalcitabine. AIDS Therapy; edited by Raphael Dolin, Henry Masur and Michael Saag: Churchill Livingstone, 2007.

Muiruri C, Ramadhani H, Bartlett J. Antiretroviral Treat in Resource-limited Settings; edited by Douglas Richman, Thomas Hope and Mario Stevenson: Springer 2015.

**3. Books**

Bartlett JA. Editor, Caring for Persons with HIV Infection. Clean Data Publishing Co., 1993.

Bartlett JA. Editor, Caring for Persons with HIV Infection. Clean Data Publishing Co., 1996.

Bartlett JA. Editor, Caring for Persons with HIV Infection. Clean Data Publishing Co., 1997.

**4. Other:**

**a. Published scientific reviews.**

Bartlett JA. HIV Infection: Current and Future Treatment. Oncology. 4:19-29, 1990.

Bartlett JA. Current and future treatment of HIV infection. Primary Care and Cancer. 11:35-50, 1991.

Bartlett JA. Clinical Simulation in the Management of HIV Disease. Medical Age Publishing, 1992.

Bartlett JA. Cryptosporidiosis: Standards of practice. PAAC Notes 5:110-112, 1993.

Bartlett JA and Sexton DJ. Decision Making in Medicine: Primary Care of HIV Infection. Hospital Practice 53-71, 1998.

Anderson AM, Bartlett JA. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. Expert Rev Anti Infect Ther 3:871-883, 2005.

Henry K, Bartlett JA, Kojic E, Flanigan TP. Antiretroviral rounds. A communication conundrum. AIDS Clin Care 17:115-116, 2005.

Anderson AML, Bartlett JA. Changing Antiretroviral Therapy in the Setting of Virologic Relapse: Review of the Current Literature. Current HIV/AIDS Reports 2006; 3:79-85.

Bartlett JA and Muro EP. Generic and branded drugs for the treatment of people living with HIV/AIDS. J Int Assoc Physicians AIDS Care 2007; 6:15-23.

Dow D and Bartlett J. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for treatment of HIV. Infectious Diseases and Therapy Journal 2014; 3:83-102

**b. Editorials, position and background papers, letters to the editor**

Bartlett JA. HIV therapeutics: An emerging science. Journal of American Medical Association. 260:3051-3052, 1989.

Bartlett JA. HIV testing in North Carolina. North Carolina Medical Journal. 51:150-151, 1990.

Dideriksen P and Bartlett JA. AIDS and Its Metaphors. Book review in New England Journal of Medicine. 322:415, 1990.

Shauank S, Albright RE and Bartlett JA. Amplifications of human immunodeficiency virus provirus from cerebrospinal fluid: Results of long-term clinical follow-up. Letter to the editor in Journal of Infectious Disease.

164:818, 1991.

Heald AE and Bartlett JA. Cryptosporidium spread in a group residential home. Letter to the editor in Annals of Internal Medicine. 6:121; 467-468, 1994.

Keitz SA, Bartlett JA. Facing the challenge of HIV. Primary care physicians have an obligation to care for those infected. N C Med J 55:10; 468-470, 1994.

Bartlett JA. The search for an AIDS vaccine: Ethical issues in the development and testing of a preventive AIDS

vaccine. Book review in Journal of Health Care Politics, Policy and Law. 22:261-263, 1996.

Bartlett JA and Maro VP. Stavudine in first-line antiretroviral regimens in resource-limited settings: time for a better solution. HIV Therapy 3:1-3; 2009.

Bartlett JA. Lack of protease inhibitor resistance following treatment failure- too good to be true? J Clin Invest 2013; 123:3704-3705.

Jaacks L, Ali M, Bartlett J, Bloomfield G, Checkley W, Gaziano T, Heimburger D, Kishore S, Kohler R, Lipska K, Manders O, Ngaruiya C, Peck R, Burroughs Pena M, Watkins D, Siegel K, Narayan V. Global Noncommunicable disease research: Opportunities and challenges. Ann Int Med 2015; doi: 10.7326/M15-1068.

Kishore S, Bartlett J, Bloomfield G, Heimburger D, Jaacks L, Lipska K, Ngaruiya C, Peck R, Burroughs Pena M, Siegel K, Manders O, Narayan V, Ali M. The Atlanta Declaration: A twenty-first century vision for US-based global noncommunicable disease research. Health Affairs Blog; published September 9, 2015.

Ibrahim G, Msuka G, Luzinge H, Tarimo C, Kulanga A, Mteta A, Bartlett J. E-learning utilization at the Kilimanjaro Christian Medical University College (KCMU Co) during the COVID-19 period. AFREHealth Newsletter October 2020.

**Editorial Service:**

Ad hoc reviewer New England Journal of Medicine, PLoS Medicine, Journal of Infectious Diseases, Clinical Infectious Diseases, Journal of the American Medical Association, Antiviral Therapy

Section Editor, Current HIV/AIDS Reports, March 2007

Academic Editor, PLoS Medicine November 2007.

Section Editor, Global/International Health; UpToDate Textbook of Medicine

**Consultant appointments:**

Primary Infection Committee, NIAID AIDS Clinical Trials Group

Combined Therapies Working Group, NIAID AIDS Clinical Trials Group

Immune Based Therapy Working Group, NIAID AIDS Clinical Trials Group

Expert Panel on HIV Infected Health Care Providers, North Carolina Department of Public Health

Chair, Data and Safety Monitoring Board, Burroughs Wellcome Protocol BW 113:34, 225:03.

Pathogenesis Focus Group, NIAID AIDS Clinical Trials Group

Chair, Treatment Intensification Focus Group, NIAID AIDS Clinical Trials Group

HIV Disease Research Agenda Committee, Adult AIDS Clinical Trials Group

Executive Committee, Adult AIDS Clinical Trials Group

When to Switch Working Group, Adult AIDS Clinical Trials Group

Intermittent Therapy Focus Group, Adult AIDS Clinical Trials Group

Antiviral Advisory Committee, United States Food and Drug Administration

AIDS Immunology and Pathogenesis Study Section, National Institutes of Health

Optimization of Antiretroviral Therapy Research Agenda Committee, AIDS Clinical Trials Group

Vice Chair, Performance Evaluation Committee, AIDS Clinical Trials Group

Executive Committee, Duke University Global Health Institute

Expert Panel on Defining Virologic Failure, World Health Organization

**Invited Talks at National and International Meetings:**

5t h European Conference on Travel Medicine and International Health; Clinical HIV/AIDS in Sub-

Saharan Africa: New Findings in a Time of Transition; Amsterdam, Netherlands, May 2007.

47th Interscience Conference on Antimicrobial Agents and Chemotherapy: HIV Infection Among

Refugees; Chicago, IL, September 2007.

**Professional awards and special recognitions:**

Eugene A. Stead, Jr. Teaching Award, 1989

Engel Society, 1990, 2000

Citizen Award, The Independent 1990

The AIDS Community Residence Association Service Award, 1991

Golden Apple Teaching Award, 1992, 1997

Key to the City of Durham from Mayor Sylvia Kerckhoff, 1994

Fellow, American College of Physicians, 1995

Councillor, North Carolina Chapter of the Infectious Diseases Society of America, 1996

Fellow, Infectious Diseases Society of America, 1997

Thomas Kinney Award for Most Outstanding Faculty Member, 1997

Alpha Omega Alpha, 1998

Humanism in Medicine Award, The Healthcare Foundation of New Jersey, 1999

Distinguished Faculty Award, Duke University Medical Alumni Association, 2000

Community Service Award, Durham-Orange County Medical Society, 2000

Donna Davis Community Advocacy Award, Adult AIDS Clinical Trials Group, 2006

Outstanding Achievement Award, North Carolina Community AIDS Fund, 2016

**Organizations and participation:**

Fellow, American College of Physicians

Member, American Association for the Advancement of Sciences

Member, American Society of Microbiology

Fellow, Infectious Diseases Society of America

Member, International AIDS Society